Browse our 650+ Publications​

Latest Publications

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Forde PM, et al.
Nature Medicine
January 2022
Authors and Affiliates
Patrick M. Forde 1,2,14, Valsamo Anagnostou 1,2,14, Zhuoxin Sun 3,4,14, Suzanne E. Dahlberg 5, Hedy L. Kindler 6, Noushin Niknafs 1, Thomas Purcell 7, Rafael Santana-Davila 7, Arkadiusz Z. Dudek 8, Hossein Borghaei 9, Mara Lanis 1, Zineb Belcaid 1, Kellie N. Smith 1,2, Archana Balan 1, James R. White 1, Christopher Cherry 1, I. K. Ashok Sivakumar 10, Xiaoshan M. Shao 10,11, Hok Yee Chan 1,2, Dipika Singh 1,2, Sampriti Thapa 1,2, Peter B. Illei 1,12, Drew M. Pardoll 1,2, Rachel Karchin 1,10,11, Victor E. Velculescu 1,2,11,12, Julie R. Brahmer 1,2 and Suresh S. Ramalingam 13; 1 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. pforde1@jhmi.edu. 2 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. pforde1@jhmi.edu. 3 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. 4 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. 5 ECOG-ACRIN Biostatistics Center, Boston, MA, USA. 6 Frontier Science Foundation, Boston, MA, USA. 7 Boston Children's Hospital, Boston, MA, USA. 8 University of Chicago Medicine, Chicago, IL, USA. 9 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 10 University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 11 Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, USA. 12 Fox Chase Cancer Center, Philadelphia, PA, USA. 13 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 14 Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD, USA. 15 Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA. 16 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 17 Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA. # Contributed equally.

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.

Pulsipher MA, et al.
Blood Cancer Discovery
January 2022
Authors and Affiliates
Michael A. Pulsipher1, Xia Han2, Shannon L. Maude3,4, Theodore W. Laetsch3,4,5, Muna Qayed6,7, Susana Rives8, Michael W. Boyer9, Hidefumi Hiramatsu10, Gregory A. Yanik11, Tim Driscoll12, G. Doug Myers13, Peter Bader14, Andre Baruchel15,16, Jochen Buechner17, Heather E. Stefanski18, Creton Kalfoglou2, Kevin Nguyen2, Edward R. Waldron2, Karen Thudium Mueller2, Harald J. Maier19, Gabor Kari19, and Stephan A. Grupp3,4 1Section of Transplantation and Cellular Therapy, Children’s Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California. 2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania. 5Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas. 6Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. 7Aflac Cancer and Blood Disorders Center, Healthcare of Atlanta, Atlanta, Georgia. 8Pediatric Hematology, Hospital Sant Joan de Déu de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain. 9Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, Utah. 10Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto City, Japan. 11Michigan Medicine Bone Marrow Transplant and Leukemia, C.S. Mott Children’s Hospital, Ann Arbor, Michigan. 12Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina. 13Pediatric Hematology and Oncology, Children’s Mercy Hospital; University of Missouri—Kansas City School of Medicine, Kansas City, Missouri. 14Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine Hospital for Children and Adolescents University Hospital Frankfurt, Frankfurt, Germany. 15Pediatric Hemato-Immunology Department, Hôpital Universitaire Robert Debré (APHP), Paris, France. 16Université de Paris et Institut de Recherche SaintLouis (EA3518), Paris, France. 17Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway. 18Department of Pediatrics, The University of Minnesota Medical School, Minneapolis, Minnesota. 19Novartis Pharmaceuticals Corporation, Basel, Switzerland.

Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma.

Olszewski AJ, et al.
Blood Advances
December 2021
Authors and Affiliates
Adam J Olszewski, MD,1,2 Anna D Chorzalska, PhD,3 Max Petersen,3 Thomas A Ollila, MD,1,2 Adam Zayac, MD,1,2 Habibe Kurt, MD,4 Diana O Treaba, MD,4 John L Reagan, MD,1,2 Andrew Hsu, MD,1,2 Pamela C Egan, MD,1,2 James Butera, MD,1,2 Rabin Niroula, MBBS,1,2 John Vatkevich,5Jordan Robison, CRA,5Ilyas Sahin, MD,1,2 Allison P Jacob, MS,6 Chelsea D Mullins, BS,6and Patrycja M Dubielecka, PhD 2,3 1 Department of Medicine, Alpert Medical School of Brown University, Providence, RI 2 Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI 3 Signal Transduction Lab, Alpert Medical School of Brown University and Rhode Island Hospital, Providence, RI 4 Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, RI 5 Lifespan Oncology Clinical Research, Rhode Island Hospital, Providence, RI 6 Adaptive Biotechnologies, Seattle, WA

Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T Cells.

Wong SW, et al.
Frontiers in Oncology
December 2021
Authors and Affiliates
Sandy W. Wong1, Nina Shah1, Guy Ledergor 1, Thomas Martin1, Jeffrey Wolf 1 ,Amy M. Shui 2, Chiung-Yu Huang2 and Joaquin Martinez-Lopez 1,3 1 Bone Marrow Transplantation and Hematologic Malignancy Unit, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA, United States, 2 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States, 3 Hospital Universitario 12 de Octubre, Complutense University, Centro Nacional de investigacion en Oncolgia (CNIO), i+12, CIBER de oncologia (CIBERONC), Madrid, Spain

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

Soumerai JD, et al.
Lancet Haematology
December 2021
Authors and Affiliates
Jacob D Soumerai, Anthony R Mato, Ahmet Dogan, Venkatraman E Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim Hochberg, Jeffrey A Barnes, Audrey M Hamilton, Jeremy S Abramson, Connie L Batlevi, Matthew J Matasar, Ariela Noy, Colette N Owens, M Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma, Chaya Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, Lauren Ramos, Natascha Nolet, Neena Mahajan, Rosalba Martignetti, Joanna Mi, Krista Scorsune, Julia Lynch, Brianne McGree, Stephanie Hughes, Clare Grieve, Lindsey E Roeker, Meghan Thompson, P Connor Johnson, Mikhail Roshal, Jane Huang, Juliana Biondo, Qun Wu, Allison Jacob, Omar Abdel-Wahab, and Andrew D Zelenetz Massachusetts General Hospital Cancer Center, Boston, MA, USA (J D Soumerai MD, E Hochberg MD, J A Barnes MD, J S Abramson MD, T Takvorian MD, L Ramos BS, N Nolet MHA, P C Johnson MD, E Simkins MPH, J Ruiters BS, S Sechio BS, D Portman BS, R Martignetti RN, K Scorsune NP, J Lynch NP, B McGree NP); Memorial-Sloan Kettering Cancer Center, New York, NY, USA (A R Mato MD, Prof A Dogan MD, V E Seshan PhD, E Joffe MD, K Flaherty BS, J Carter PA, A M Hamilton MD, C L Batlevi MD, M J Matasar MD, Prof A Noy MD, C N Owens MD, M L Palomba MD, A Kumar MD, A Ni PhD, M Choma BS, C Friedman BA, P Chadha MPH, N Mahajan NP, J Mi NP, S Hughes BS, C Grieve BA, L E Roeker MD, M Thompson MD, M Roshal MD, Prof O Abdel-Wahab MD, Prof A D Zelenetz MD); Beigene, San Mateo, CA, USA (J Huang MD); Genentech, San Francisco, CA, USA (J Biondo MD, Q Wu PhD); Adaptive Biotechnologies, Seattle, WA, USA (A Jacob MS)

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.

Langerhorst P, et al.
Clinical Chemistry
November 2021
Authors and Affiliates
Pieter Langerhorst,a, Somayya Noori ,b, Marina Zajec,b,c Yolanda B. De Rijke,c Jolein Gloerich,a Alain J. van Gool,a He´le`ne Caillon,d Irma Joosten,a Theo M. Luider,b Jill Corre,e Martijn M. VanDuijn,b, Thomas Dejoie,d, and Joannes F.M. Jacobsa aDepartment of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; bDepartment of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands; cDepartment of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands; dLaboratoire de Biochimie, Centre Hospitalier Universitaire (CHU), Nantes, France; eUnite de Genomique du Myelome, Institute Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.

Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.

Lonial S, et al.
American Cancer Society Cancer
November 2021
Authors and Affiliates
Sagar Lonial, MD 1; Hans C. Lee, MD2; Ashraf Badros, MD 3; Suzanne Trudel, MD4; Ajay K. Nooka, MD 1; Ajai Chari, MD 5; Al-Ola Abdallah, MD6; Natalie Callander, MD7; Douglas Sborov, MD8; Attaya Suvannasankha, MD9; Katja Weisel, MD10; Peter M. Voorhees, MD11; Lynsey Womersley, MSc12; January Baron, MS13; Trisha Piontek, BSN13; Eric Lewis, MD14; Joanna Opalinska, MD13; Ira Gupta, MD13; and Adam D. Cohen, MD15 1Winship Cancer Institute, Emory University, Atlanta, Georgia; 2Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas; 3Greenebaum Cancer Center, Bone Marrow Transplant Program, University of Maryland at Baltimore, Baltimore, Maryland; 4Princess Margaret Cancer Center, Toronto, Ontario, Canada; 5Icahn School of Medicine at Mount Sinai, New York, New York; 6University of Kansas Cancer Center, Fairway, Kansas; 7Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; 8Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; 9Indiana University Cancer Center, Indianapolis, Indiana; 10Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany; 11Levine Cancer Institute, Atrium Health, Charlotte, North Carolina; 12GlaxoSmithKline, Stockley Park, United Kingdom; 13GlaxoSmithKline, Upper Providence, Pennsylvania; 14GlaxoSmithKline, Research Triangle Park, North Carolina; 15Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

Costa LJ, et al.
Journal of Clinical Oncology
November 2021
Authors and Affiliates
Luciano J. Costa, MD, PhD1,2; Saurabh Chhabra, MD3; Eva Medvedova, MD4; Bhagirathbhai R. Dholaria, MD5; Timothy M. Schmidt, MD6; Kelly N. Godby, MD1,2; Rebecca Silbermann, MD4; Binod Dhakal, MD3; Susan Bal, MD1,2; Smith Giri, MD1,2; Anita D’Souza, MD3; Aric Hall, MD6; Pamela Hardwick, RN2; James Omel, MD7; Robert F. Cornell, MD5; Parameswaran Hari, MD3; and Natalie S. Callander, MD6 1Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL 2O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, AL 3Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 4Oregon Health & Science University, Portland, OR 5Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 6University of Wisconsin, Madison, WI 7Independent Patient Advocate, Omaha, NE

Characterizing the BCR repertoire during lymphocyte reduction and recovery mediated by cyclophosphamide and granulocyte-macrophage colony-stimulating factor

Li J, et al.
November 2021
Authors and Affiliates
Jun Li 1, Yuehong Li 1, Suhong Sun 2, Liwen Yang 1, Long Ma 1, Bin Shi 1, Rui Ma 1, Xinsheng Yao 3; 1 Department of Immunology, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Zunyi Medical University, Zunyi City, China. 2 Department of Breast Surgery, The First Affiliated Hospital of ZunYi Medical University, Zunyi City, China. 3 Department of Immunology, Center of Immunomolecular Engineering, Innovation & Practice Base for Graduate Students Education, Zunyi Medical University, Zunyi City, China. Electronic address: immunology01@126.com.

Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8 + T-Cell Responses

He X, et al.
November 2021
Authors and Affiliates
Xuedan He 1, Shiqi Zhou 1, Breandan Quinn 1, Wei-Chiao Huang 1, Dushyant Jahagirdar 2, Michael Vega 3, Joaquin Ortega 2, Mark D Long 4, Fumito Ito 5,6,7, Scott I Abrams 5, Jonathan F Lovell 1; 1 University at Buffalo, State University of New York, Buffalo, NY, 14260, USA. 2 Department of Anatomy and Cell Biology, McGill University Montreal, Quebec, H3A1Y2, Canada. 3 Division of Research and Innovation Partnerships, Northern Illinois University, DeKalb, IL, 60115, USA. 4 Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center (RPCCC), Buffalo, NY, 14263, USA. 5 Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. 6 Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. 7 Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Previous Next